off-label use of glp-1 agonists for obesity in 2016 Emerging Role Obesity: A Comprehensive Review of Randomised Controlled Trials Liraglutide: A Generic Option for

Research into semaglutide-related vision injuries has expanded significantly in recent years as physicians, researchers, and regulators investigate reports of NAION among patients using GLP-1 medications

Enhanced GIP secretion in obesity is associated with biochemical alteration and miRNA contribution to the development of liver steatosis

They contain the same active ingredients but carry FDA approval for type 2 diabetes rather than weight loss

Follow-up measurements taken during the 90 days on either side of these post-index dates were valid, with the closest measurement to 180/365 days post-index used as the follow-up value if multiple measurements were available